Palestinian Authority plans to legalize magic mushrooms to treat mental illness
Pennsylvania could become a pioneer in the study of psilocybin as a treatment for mental illness under a bill that was introduced last month in the House of Representatives and is due for a vote by the Committee of health on Tuesday, November 16 in Harrisburg.
The proposed legislation, the Psilocybin Public Health Benefits Act, would establish a framework for clinical studies of psilocybin, the active ingredient in the psychedelic drug known as magic mushrooms.
“Treatment-resistant depression is a major challenge for contemporary psychiatry,” said Smith. “We need more options. “
Good report from @InqBrubaker on a rare bipartisan effort to get psilocybin treatment [potentially] possible in Pennsylvania. https://t.co/VMmc8yJSkG
– Abraham Gutman (@abgutman) November 15, 2021
This would give researchers a loophole to bypass federal rules that still classify the substance as having no medical purpose, despite mounting evidence showing that it does.
Experts and lawyers have said that although the bill is never enacted, its introduction is a good sign that psilocybin could potentially become a therapeutic treatment for PTSD, severe cases of depression and more.
Last year, residents of Oregon voted to decriminalize and legalize the therapeutic use of the substance, and Texas recently approved the study of psychedelic therapy for military veterans.
Republican Tracy Pennycuick of Montgomery County and Democrat Jennifer O’Mara of Delaware County discuss the benefits of psychedelic medicine in the treatment of post-traumatic stress disorder, traumatic brain injury and other mental illnesses, especially for veterans, first responders and their families.
“A growing body of research gives reason to hope that psilocybin, administered in a controlled setting, will be the most effective tool available to us in the fight against suicide, opioids, and the global mental health crisis looming over us. the Commonwealth, ”Pennycuick and O’Mara wrote in a note to colleagues.
In October 2018 and again in November 2019, the United States Food and Drug Administration granted breakthrough psilocybin therapy designation for treatment-resistant depression based on research showing the psychedelic compound offered significant improvement in blood levels. depressive symptoms compared to current treatments.
Under the bill, which was officially filed with 19 cosponsors on Wednesday, October 6, the state’s health ministry would allow at least two entities to “plant, grow and cultivate a natural psilocybin mushroom product. only for use in clinical studies of psilocybin. ”
Pennycuick herself is an Army veteran who lives with PTSD. She said Moment Marijuana that she has “great compassion for all who seek treatment options” and that she is inspired by the first reports she read about the compound’s potential effectiveness.
“With Pennsylvania home to the fourth largest veteran population in the United States, it makes sense that we are among the first to take action on clinical studies that could help our military men and women,” he said. she declared.
Brett Waters, a New York attorney who founded Reason for Hope, a nonprofit that promotes psychedelic-assisted psychotherapy, told the Philadelphia Inquirer that current treatments for PTSD and depression are not very effective. .
“It has limited effectiveness for some people and no effectiveness for many people. We must do better. The real goal of this effort is to prevent suicides, opioid overdoses and alcohol-related deaths, ”Waters said.